221 related articles for article (PubMed ID: 34930105)
1. Targeting CK2 mediated signaling to impair/tackle SARS-CoV-2 infection: a computational biology approach.
Miranda J; Bringas R; Fernandez-de-Cossio J; Perera-Negrin Y
Mol Med; 2021 Dec; 27(1):161. PubMed ID: 34930105
[TBL] [Abstract][Full Text] [Related]
2. Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection.
Ramón AC; Pérez GV; Caballero E; Rosales M; Aguilar D; Vázquez-Blomquist D; Ramos Y; Rodríguez-Ulloa A; Falcón V; Rodríguez-Moltó MP; Yang K; Perera Y; Perea SE
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336959
[TBL] [Abstract][Full Text] [Related]
3. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.
Perera Y; Farina HG; Gil J; Rodriguez A; Benavent F; Castellanos L; Gómez RE; Acevedo BE; Alonso DF; Perea SE
Mol Cancer Ther; 2009 May; 8(5):1189-96. PubMed ID: 19417160
[TBL] [Abstract][Full Text] [Related]
4. CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome.
Perera Y; Ramos Y; Padrón G; Caballero E; Guirola O; Caligiuri LG; Lorenzo N; Gottardo F; Farina HG; Filhol O; Cochet C; Perea SE
Mol Cell Biochem; 2020 Jul; 470(1-2):63-75. PubMed ID: 32405972
[TBL] [Abstract][Full Text] [Related]
5. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
Perea SE; Baladrón I; Valenzuela C; Perera Y
Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
[TBL] [Abstract][Full Text] [Related]
6. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG
Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334
[TBL] [Abstract][Full Text] [Related]
7. CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells.
Ramón AC; Basukala O; Massimi P; Thomas M; Perera Y; Banks L; Perea SE
Viruses; 2022 Jul; 14(8):. PubMed ID: 36016303
[TBL] [Abstract][Full Text] [Related]
8. Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
Perera Y; Melão A; Ramón AC; Vázquez D; Ribeiro D; Perea SE; Barata JT
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471246
[TBL] [Abstract][Full Text] [Related]
9. The Global Phosphorylation Landscape of SARS-CoV-2 Infection.
Bouhaddou M; Memon D; Meyer B; White KM; Rezelj VV; Correa Marrero M; Polacco BJ; Melnyk JE; Ulferts S; Kaake RM; Batra J; Richards AL; Stevenson E; Gordon DE; Rojc A; Obernier K; Fabius JM; Soucheray M; Miorin L; Moreno E; Koh C; Tran QD; Hardy A; Robinot R; Vallet T; Nilsson-Payant BE; Hernandez-Armenta C; Dunham A; Weigang S; Knerr J; Modak M; Quintero D; Zhou Y; Dugourd A; Valdeolivas A; Patil T; Li Q; Hüttenhain R; Cakir M; Muralidharan M; Kim M; Jang G; Tutuncuoglu B; Hiatt J; Guo JZ; Xu J; Bouhaddou S; Mathy CJP; Gaulton A; Manners EJ; Félix E; Shi Y; Goff M; Lim JK; McBride T; O'Neal MC; Cai Y; Chang JCJ; Broadhurst DJ; Klippsten S; De Wit E; Leach AR; Kortemme T; Shoichet B; Ott M; Saez-Rodriguez J; tenOever BR; Mullins RD; Fischer ER; Kochs G; Grosse R; García-Sastre A; Vignuzzi M; Johnson JR; Shokat KM; Swaney DL; Beltrao P; Krogan NJ
Cell; 2020 Aug; 182(3):685-712.e19. PubMed ID: 32645325
[TBL] [Abstract][Full Text] [Related]
10. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.
Rosales M; Pérez GV; Ramón AC; Cruz Y; Rodríguez-Ulloa A; Besada V; Ramos Y; Vázquez-Blomquist D; Caballero E; Aguilar D; González LJ; Zettl K; Wiśniewski JR; Yang K; Perera Y; Perea SE
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356831
[TBL] [Abstract][Full Text] [Related]
11. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Perea SE; Baladron I; Garcia Y; Perera Y; Lopez A; Soriano JL; Batista N; Palau A; Hernández I; Farina H; Garcia I; Gonzalez L; Gil J; Rodriguez A; Solares M; Santana A; Cruz M; Lopez M; Valenzuela C; Reyes O; López-Saura PA; González CA; Diaz A; Castellanos L; Sanchez A; Betancourt L; Besada V; González LJ; Garay H; Gómez R; Gómez DE; Alonso DF; Perrin P; Renualt JY; Sigman H; Herrera L; Acevedo B
Mol Cell Biochem; 2011 Oct; 356(1-2):45-50. PubMed ID: 21735096
[TBL] [Abstract][Full Text] [Related]
12. Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.
Cheng K; Martin-Sancho L; Pal LR; Pu Y; Riva L; Yin X; Sinha S; Nair NU; Chanda SK; Ruppin E
Mol Syst Biol; 2021 Nov; 17(11):e10260. PubMed ID: 34709707
[TBL] [Abstract][Full Text] [Related]
13. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.
Cruz LR; Baladrón I; Rittoles A; Díaz PA; Valenzuela C; Santana R; Vázquez MM; García A; Chacón D; Thompson D; Perera G; González A; Reyes R; Torres L; Pérez J; Valido Y; Rodriguez R; Vázquez-Bloomquist DM; Rosales M; Ramón AC; Pérez GV; Guillén G; Muzio V; Perera Y; Perea SE;
ACS Pharmacol Transl Sci; 2021 Feb; 4(1):206-212. PubMed ID: 33615173
[TBL] [Abstract][Full Text] [Related]
14. Long-chain polyphosphates impair SARS-CoV-2 infection and replication.
Ferrucci V; Kong DY; Asadzadeh F; Marrone L; Boccia A; Siciliano R; Criscuolo G; Anastasio C; Quarantelli F; Comegna M; Pisano I; Passariello M; Iacobucci I; Monica RD; Izzo B; Cerino P; Fusco G; Viscardi M; Brandi S; Pierri BM; Borriello G; Tiberio C; Atripaldi L; Bianchi M; Paolella G; Capoluongo E; Castaldo G; Chiariotti L; Monti M; De Lorenzo C; Yun KS; Pascarella S; Cheong JH; Kim HY; Zollo M
Sci Signal; 2021 Jul; 14(690):. PubMed ID: 34230209
[TBL] [Abstract][Full Text] [Related]
15. The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines.
Cirigliano SM; Díaz Bessone MI; Berardi DE; Flumian C; Bal de Kier Joffé ED; Perea SE; Farina HG; Todaro LB; Urtreger AJ
Cancer Cell Int; 2017; 17():42. PubMed ID: 28373828
[TBL] [Abstract][Full Text] [Related]
16. Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
Schuhenn J; Meister TL; Todt D; Bracht T; Schork K; Billaud JN; Elsner C; Heinen N; Karakoese Z; Haid S; Kumar S; Brunotte L; Eisenacher M; Di Y; Lew J; Falzarano D; Chen J; Yuan Z; Pietschmann T; Wiegmann B; Uebner H; Taube C; Le-Trilling VTK; Trilling M; Krawczyk A; Ludwig S; Sitek B; Steinmann E; Dittmer U; Lavender KJ; Sutter K; Pfaender S
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35131898
[TBL] [Abstract][Full Text] [Related]
17. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
18. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE; Reyes O; Baladron I; Perera Y; Farina H; Gil J; Rodriguez A; Bacardi D; Marcelo JL; Cosme K; Cruz M; Valenzuela C; López-Saura PA; Puchades Y; Serrano JM; Mendoza O; Castellanos L; Sanchez A; Betancourt L; Besada V; Silva R; López E; Falcón V; Hernández I; Solares M; Santana A; Díaz A; Ramos T; López C; Ariosa J; González LJ; Garay H; Gómez D; Gómez R; Alonso DF; Sigman H; Herrera L; Acevedo B
Mol Cell Biochem; 2008 Sep; 316(1-2):163-7. PubMed ID: 18575815
[TBL] [Abstract][Full Text] [Related]
19. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
20. Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization.
Gottardo MF; Capobianco CS; Sidabra JE; Garona J; Perera Y; Perea SE; Alonso DF; Farina HG
Sci Rep; 2020 Sep; 10(1):14689. PubMed ID: 32895446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
